Rezolute, Inc. RZLT
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Rezolute, Inc. (RZLT) is a healthcare company listed in the US with a market value of about $354M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -42%.
About Rezolute
Rezolute is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 103% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$78M | -$74M | -$68M | -$52M | -$41M | -$21M | -$20M | -$30M | -$30M | -$20M |
| Free cash flow | — | — | — | -$45M | — | — | -$24M | -$15M | -$14M | -$14M |
| EPS (diluted) | $-0.75 | $-0.98 | $-1.33 | $-1.01 | $-2.32 | $-2.72 | $-3.54 | $-18.41 | $-27.01 | $-28507.02 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -64.5% | -38.6% | -45.1% | -37.3% | -22.1% | -44.6% | -208.5% | -855.8% | — | -188.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $10.40, 185% above the current price; targets range from $6.00 to $15.00; the consensus rating is “Strong buy”; expected EPS is $-0.65 for the fiscal year ending June 30, 2027.
Frequently asked questions
Does Rezolute pay a dividend?
Not currently.
Is Rezolute a good stock to buy?
We do not give buy or sell advice. Rezolute scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.